Lewy body disease

Southern Medical Journal

Volumn 89, Issue 12, 1996, Pages 1174-1180

  Smith, Tamara A ^a,b   Prayson, Richard A ^a,b  

^a Cleveland Clinic Foundation ^*

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; LEWY BODY; NERVE DEGENERATION; PARKINSON DISEASE; PATHOGENESIS;

ALZHEIMER DISEASE; HUMANS; PARKINSON DISEASE;

EID: 0030480803     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199612000-00008     Document Type: Article

References (68)

1. Lewy FH: Paralysis agitans. Pathologische Anatomie. Handbuch der Neurologie. Lewandowsky M (ed). Berlin, Germany, Springer-Verlag, 1912, pp 920-933
2. Forno LS: Pathology of Parkinson's disease: the importance of the substantia nigra and Lewy bodies. Parkinson's Disease. Stern GM (ed). Baltimore, Md, Johns Hopkins University Press, 1990, pp 185-238
3. Duffy PE, Tennyson VM: Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J Neuropathol Exp Neurol 1965; 24:398-414
4. Forno LS, Norville RL: Ultrastructure of Lewy bodies in stellate ganglion. Acta Neuropathol 1976; 34:183-197
5. Hansen LA, Galasko D: Lewy body disease. Curr Opin Neurol Neurosurg 1992; 5:889-894
6. Schmidt ML, Murray J, Lee VM-Y, et al: Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991; 139:53-65
7. Kosaka K: Lewy bodies in the cerebral cortex: report of three cases. Acta Neuropathol (Berl) 1978; 42:127-134
8. Yoshimura M: Cortical changes in the parkinsonian brain: a contribution to the delineation of "diffuse Lewy body disease." J Neurol 1983; 229:17-32
9. Hill W, Lee VM-Y, Hurtig H, et al: Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol 1991; 309:150-160
10. Schmidt ML, Murray J, Lee VM-Y, et al: Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991; 139:53-65
11. Bancher C, Lassmann H, Budka H, et al: An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 1989; 48:81-93
12. Kuzuhara S, Mori H, Izumiyama N, et al: Lewy bodies are ubiquitinated, a light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1988; 75:345-353
13. Leigh P, Probst A, Gale G, et al: New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol (Berl) 1989; 79:61-72
14. Leestma JF, Andrews JM: The fine structure of the Marinesco body. Arch Pathol 1969; 88:431-436
15. Perry RH, Irving D, Tomlinson BE: Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 1991; 102:121
16. Newcastle NB: Degenerative diseases of the central nervous system. Textbook of Neuropathology. Davis RL, Robertson DM (eds). Baltimore, Md, Williams & Wilkins, 1991, pp 904-961
17. Pearce JMS: Parkinson's Disease and Its Management. New York, Oxford University Press, 1992, pp 4-25
18. Jellinger K, Riederer P: Dementia in Parkinson's disease and (pre)senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neurol 1984; 40:199-210
19. Korczyn AD: Parkinson's disease. Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (eds). New York, Raven Press, 1995, pp 1479-1484
20. Hughes AJ, Daniel SE, Blankson S, et al: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148
21. Braak H, Braak E, Yilmazer D, et al: Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88:495-500
22. Jager WA, Den Hartog, Bethlem J: The distribution of Lewy bodies of the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23:283-290
23. Kandel ER, Schwartz JH, Jessell TM: Principles of Neural Science. New York, Elsevier Science Publishing Co, 3rd Ed, 1991, pp 606-607, 647-659, 863-865
24. Treves TA, Chandra V, Korczyn AD: Parkinson's and Alzheimer's diseases: epidemiological comparison. Neuroepidemiology 1993; 12:336-349
25. Paddison RM, Griffith RP: Occurrence of Parkinson's disease in black patients at Charity Hospital in New Orleans. Neurology 1993; 24:688-691
26. Marsden CD: Parkinson's disease. Postgrad Med J 1992; 68:538-543
27. Langston JW, Ballard P, Tetried JW, et al: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:970-980
28. Rossetti ZL, Sotgiu A, Sharp D, et al: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 1988; 37:4573-4574
29. Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Inhibition of NAD-linked substrate oxidation by its metabolite 1-methyl-4-phenylpyridinium. J Neurochem 1986; 46:1501-1507
30. Sian J, Dexter DT, Lees AJ, et al: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36:348-355
31. Sian J, Dexter DT, Lees AJ, et al: Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994; 36:356-361
32. Mann VM, Cooper JM, Daniel SE, et al: Complex 1, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994; 36:876-881
33. Nakano M: A possible mechanism of iron neurotoxicity. Eur Neurol 1993; 33(suppl):44-51
34. Schapira AHV: Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov Disord 1994; 9:125-138
35. DiDonato S, Zeviani M, Giovannini P, et al: Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 1993; 43:2262-2268
36. Dexter DT, Sian J, Rose S, et al: Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35:38-44
37. Cardellach F, Martí MJ, Fernández-Solá J, et al: Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993; 43:2258-2262
38. Tooyami I, Kawamata T, Walker D, et al: Loss of basic fibroblastic growth factor in substantia nigra neurons in Parkinson's disease. Neurology 1993; 43:372-376
39. Moroo I, Yamada T, Makeno H, et al: Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol 1994; 87:343-348
40. Vieregge P: Genetic factors in the etiology of idiopathic Parkinson's disease. J Neurol Transm 1994; 8:1-37
41. Lazzarini AM, Myers RH, Zimmerman TR Jr, et al: A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 1994; 44:499-506
42. Gasser T, Wszolek ZK, Trofatter J, et al: Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994; 36:387-396
43. Waters CH, Miller CA: Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994; 35:59-64
44. Golbe LI, DiIorio G, Bonavita V, et al: A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27:276-282
45. Martin WE, Young WI, Anderson VE: Parkinson's disease, a genetic study. Brain 1973; 96:495-506
46. Kondo K, Kurland LT: Parkinson's disease, genetic analysis and evidence of a multifactorial etiology. Mayo Clin Proc 1973; 48:465-474
47. Payami H, Bernard S, Larsen K, et al: Genetic anticipation in Parkinson's disease. Neurology 1995; 45:135-138
48. Johnson WG, Hodge SE, Duvoisin RC: Twin studies and the genetics of Parkinson's disease. Mov Disord 1980; 5:187-194
49. Smith CAD, Gough AC, Leigh PN, et al: Debrisoquin hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339:1375-1377
50. Gibb WRG, Luthert PJ, Janota I, et al: Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry 1992; 52:182-192
51. Yoshimura M: Cortical changes in the parkinsonism brain: a contribution to the delineation of "diffuse Lewy body disease." J Neurol 1983; 229:17-32
52. Ikeda K, Ikeda S, Yoshimura T, et al: Idiopathic parkinsonism with Lewy-type inclusions in the cerebral cortex, a case report. Acta Neuropathol (Berl) 1978; 41:165-168
53. Kosaka K, Yoshimura M, Ikeda K, et al: Diffuse type of Lewy body disease: progressive dementia and abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin Neuropathol 1984; 3:185-192
54. Dickson DW, Davies P, Mayeux R, et al: Diffuse Lewy body disease, neuropathological and biochemical studies of six patients. Acta Neuropathol (Berl) 1987; 75:8-15
55. Ditter SM, Mirra SS: Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987; 37:754-760
56. Byrne EJ, Lennox G, Lowe J, et al: Diffuse Lewy body disease: the clinical features. Adv Neurol 1990; 53:283-286
57. Kosaka K, Tsuchiya K, Yoshimura M: Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 1988; 7:299-305
58. Hansen L, Salmon D, Galasko D, et al: The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990; 40:1-8
59. Hakim AM, Mathieson G: Dementia in Parkinson's disease: a neuropathologic study. Neurology 1979; 29:1209-1214
60. Boller F, Mitzutani T, Roessmann U, et al: Parkinson's disease, dementia, and Alzheimer's disease: clinicopathological correlations. Ann Neurol 1980; 7:329-335
61. Gibb WRG, Mann DMA, Mountjoy CQ, et al: A pathological study of the association between Lewy body disease and Alzheimer's disease. Adv Neurol 1990; 53:55-59
62. Förstl H, Burns A, Luthert P, et al: The Lewy body variant of Alzheimer's disease, clinical and pathological findings. Br J Psychiatry 1993; 162:385-392
63. Hansen LA, Masliah E, Terry RD, et al: A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 1989; 78:194-201
64. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923
65. ∈4) with late onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472
66. ∈-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosd Lett 1994; 182:63-65
67. ∈4 allele frequency intermediate between controls and Alzheimer's disease. Neurosci Lett 1994; 182:1-2
68. Bergeron C, Pollanen M: Lewy bodies in Alzheimer's disease - one or two diseases? Ahzheimer's Dis Assoc Disord 1989; 3:197-204